Scholar Rock vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Scholar Rock Holding Corp (SRRK)

Q3 20266 Aug – 15 Sep 2026

▲3

FDA Approves Scholar Rock's First SMA Drug; Analysts Split on What's Next

FDA approval of Isembyld (apitegromab) for SMA The FDA approved Isembyld, the first SMA drug that targets muscle directly, for patients 2 and older already on SMN2 therapy. This turns Scholar Rock into a commercial company with a U.S. launch underway, a major positive driver.
This is the single biggest new event of the period and the main reason SRRK is moving.
Regulatory path cleared in U.S., Europe, Japan Scholar Rock removed a problem fill-finish plant from its application, kept its FDA decision date, and got Japan's OK that no extra trials are needed. Europe will be resubmitted. This lowers the risk of delays and opens more markets.
It explains why the approval came through and how the company can sell the drug beyond the U.S.
Analyst downgrade and price-target split after approval Barclays downgraded SRRK to Equal Weight, saying the approval was already priced in and the non-SMA pipeline needs more proof. Other firms raised targets into the $70s-$80s. This tug-of-war explains recent share swings.
It is the main counterweight to the good news and shows why the stock fell even after approval.
Commercial launch and pricing underway Isembyld is shipping, with a patient support program for insurance and infusions. Announced pricing slightly beat analyst estimates. Early sales execution will now drive the stock more than approval headlines.
It shows the next phase for SRRK: turning approval into actual revenue.

August 20266 Aug – 15 Sep 2026

▲3

FDA Approves Scholar Rock's First SMA Drug; Analysts Split on What's Next

FDA approval of Isembyld (apitegromab) for SMA The FDA approved Isembyld, the first SMA drug that targets muscle directly, for patients 2 and older already on SMN2 therapy. This turns Scholar Rock into a commercial company with a U.S. launch underway, a major positive driver.
This is the single biggest new event of the period and the main reason SRRK is moving.
Regulatory path cleared in U.S., Europe, Japan Scholar Rock removed a problem fill-finish plant from its application, kept its FDA decision date, and got Japan's OK that no extra trials are needed. Europe will be resubmitted. This lowers the risk of delays and opens more markets.
It explains why the approval came through and how the company can sell the drug beyond the U.S.
Analyst downgrade and price-target split after approval Barclays downgraded SRRK to Equal Weight, saying the approval was already priced in and the non-SMA pipeline needs more proof. Other firms raised targets into the $70s-$80s. This tug-of-war explains recent share swings.
It is the main counterweight to the good news and shows why the stock fell even after approval.
Commercial launch and pricing underway Isembyld is shipping, with a patient support program for insurance and infusions. Announced pricing slightly beat analyst estimates. Early sales execution will now drive the stock more than approval headlines.
It shows the next phase for SRRK: turning approval into actual revenue.

Latest6 Aug – 15 Sep 2026

▲3

FDA Approves Scholar Rock's First SMA Drug; Analysts Split on What's Next

FDA approval of Isembyld (apitegromab) for SMA The FDA approved Isembyld, the first SMA drug that targets muscle directly, for patients 2 and older already on SMN2 therapy. This turns Scholar Rock into a commercial company with a U.S. launch underway, a major positive driver.
This is the single biggest new event of the period and the main reason SRRK is moving.
Regulatory path cleared in U.S., Europe, Japan Scholar Rock removed a problem fill-finish plant from its application, kept its FDA decision date, and got Japan's OK that no extra trials are needed. Europe will be resubmitted. This lowers the risk of delays and opens more markets.
It explains why the approval came through and how the company can sell the drug beyond the U.S.
Analyst downgrade and price-target split after approval Barclays downgraded SRRK to Equal Weight, saying the approval was already priced in and the non-SMA pipeline needs more proof. Other firms raised targets into the $70s-$80s. This tug-of-war explains recent share swings.
It is the main counterweight to the good news and shows why the stock fell even after approval.
Commercial launch and pricing underway Isembyld is shipping, with a patient support program for insurance and infusions. Announced pricing slightly beat analyst estimates. Early sales execution will now drive the stock more than approval headlines.
It shows the next phase for SRRK: turning approval into actual revenue.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.